At SLEEP 2009, Ventus Medical highlighted clinical data from three poster presentations supporting PROVENT Sleep Apnea Therapy’s clinical utility in treating mild, moderate, and severe OSA.
PROVENT Therapy is a prescription device indicated for the treatment of OSA. It is a disposable, prescription treatment that works across mild, moderate, and severe OSA. The treatment utilizes nasal expiratory positive airway pressure (EPAP) and has been clinically shown to reduce sleep apnea. It incorporates a novel MicroValve design that is placed over the nostrils and secured with hypoallergenic adhesive. During inhalation, the valve opens, allowing nearly unobstructed airflow, and during exhalation, the valve closes, limiting airflow through two small openings, which increases expiratory pressure.
The reported data suggests that positive end-expiratory pressure is the mechanism of action by which PROVENT Therapy helps patients with sleep-disordered breathing.1
“An estimated 50 million people in the United States suffer from obstructive sleep apnea, yet there are few treatment options that meet all patients’ needs. PROVENT Therapy offers a new alternative that is discreet, easy to use, disposable, and comfortable to use throughout the night, regardless of a patient’s sleep position,” explained Philip Westbrook, MD, Emeritus Professor of Medicine at UCLA and Ventus Medical’s Chief Medical Officer. “These new data offer additional evidence that PROVENT Therapy is clinically proven and truly designed with the patient’s needs in mind.”
The three poster sessions containing the data were (1) Mechanism of Action Study, (2) Modeling the Effectiveness of PROVENT Therapy Compared to CPAP, and (3) PROVENT Therapy Pooled Data Analysis.
1. Hwang D, Patel A, Chen G, Ayappa I, Rapoport DM. Nasal EPAP—Physiologic Mechanism of Action, June 9, 2009, poster presentation at SLEEP 2009, the 23rd Annual Meeting of the Associated Professional Sleep Societies. Abstract 0591.
